Next Article in Journal
Methodologies and Tools Used Today for Measuring Iron Load
Previous Article in Journal
Viral Hepatitis B and C. Cure or Treatment?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Thalassemia Reports
Volume 4
Issue 3
10.4081/thal.2014.4860
thalassrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Thalassemia Reports is published by MDPI from Volume 12 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Overview of Chelation Recommendations for Thalassaemia and Sickle Cell Disease

by
Banu Kaya
Barts Health NHS Trust, Royal London Hospital, London, UK
Thalass. Rep. 2014, 4(3), 4860; https://doi.org/10.4081/thal.2014.4860
Submission received: 25 September 2014 / Revised: 5 November 2014 / Accepted: 1 December 2014 / Published: 4 December 2014

Abstract

The long term consequences of iron toxicity are mostly reversible with effective iron chelation therapy. Recommendations for use of chelation therapy in transfusion dependent thalassaemia (TDT), sickle cell disease (SCD) and non transfusion dependent thalassaemia (NTDT) continue to evolve as our knowledge and clinical experience increases. Improved chelation options including drug combinations and a better understanding of condition specific factors may help to improve efficiency of chelation regimens and meet the needs of patients more effectively.
Keywords: iron toxicity; thalassaemia; sickle cell disease; chelation therapy; drug iron toxicity; thalassaemia; sickle cell disease; chelation therapy; drug

Share and Cite

MDPI and ACS Style

Kaya, B. Overview of Chelation Recommendations for Thalassaemia and Sickle Cell Disease. Thalass. Rep. 2014, 4, 4860. https://doi.org/10.4081/thal.2014.4860

AMA Style

Kaya B. Overview of Chelation Recommendations for Thalassaemia and Sickle Cell Disease. Thalassemia Reports. 2014; 4(3):4860. https://doi.org/10.4081/thal.2014.4860

Chicago/Turabian Style

Kaya, Banu. 2014. "Overview of Chelation Recommendations for Thalassaemia and Sickle Cell Disease" Thalassemia Reports 4, no. 3: 4860. https://doi.org/10.4081/thal.2014.4860

APA Style

Kaya, B. (2014). Overview of Chelation Recommendations for Thalassaemia and Sickle Cell Disease. Thalassemia Reports, 4(3), 4860. https://doi.org/10.4081/thal.2014.4860

Article Metrics

Back to TopTop